Company and Stock Identity

How UpDoc Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
This is the group's 3am question in its sharpest form. The product does not just raise an alert, it acts inside a physician-written plan, so ask exactly where the defined clinical boundaries sit, what happens when a patient falls outside them, and who is on the other end. Keep the two things separate as well: UpDoc says its insulin management system is FDA cleared today, while the cardiovascular system is a 39-month federal development award, not a cleared product.

UpDoc's own site says the company is backed by Mayo Clinic, Eli Lilly and the American Diabetes Association. No ownership change was found. Checked on 2026-10-10.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... UpDoc ... Company source

A federal agency picked UpDoc to build an autonomous heart care AI, with Microsoft, OpenAI and NVIDIA alongside

UpDoc said on 9 September 2026 that ARPA-H selected it to lead development of an autonomous clinical AI system for managing cardiovascular disease under the ADVOCATE program, with an award of up to 9.2 million dollars over 39 months and with Microsoft, OpenAI and NVIDIA joining the initiative. The company describes its current FDA-cleared insulin management system as combining medical device functionality with conversational AI to support care within physician-prescribed treatment plans and defined clinical boundaries. UpDoc quotes ARPA-H programme manager Dr Haider Warraich calling ADVOCATE an unprecedented level of coordination across the federal health enterprise, coordinated with the FDA and other agencies, and cites a United States cardiovascular disease cost of more than 400 billion dollars a year.

Why it matters: The important detail for a buyer is the line between the two systems. The insulin product is cleared and sellable now; the cardiovascular one is a development award running 39 months, so nothing about it is a product a health system can buy this year. The award still matters, because a federal programme funding autonomous clinical action, coordinated with the FDA, is a signal about where that regulatory boundary may move. Until it does, treat an autonomous care claim the way you would treat any device claim and ask for the clearance that covers the exact action.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers page names no job titles or offices. It describes the team as physicians, engineers, operators, researchers and builders, and points candidates to an open roles link or a careers email.

Qualification signal: A cleared device that acts on insulin carries far more regulatory weight than software that only suggests, so people who have taken that kind of autonomy through the FDA are the rare hire. Clinical pharmacology and endocrinology knowledge counts as much as engineering here.

Check current roles at UpDoc. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Virtual care, population health, nursing, service-line leadership, care management, and payer teams
Primary use case
Monitor patients outside the facility and route clinically meaningful changes to a care team
Typical deployment
Usually combines connected devices, patient applications, analytics, EHR integration, and either vendor or health-system clinical staffing

Evidence questions

  • Which outcomes improved for the target condition and patient population?
  • What are adherence, dropout, false alert, and escalation rates?
  • Does the evidence include the same staffing model being proposed to us?

Regulatory and workflow questions

  • Which device and software components require authorization for their stated use?
  • Who holds clinical responsibility for alerts at every hour?
  • What happens when readings are missing, implausible, delayed, or ignored?

Data and contract questions

  • Which device, symptom, location, and patient-reported data are collected?
  • How are identity, consent, device security, and home connectivity handled?
  • Can alert history, interventions, and outcomes be exported for independent review?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources